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ABSTRACT
Tumour heterogeneity is a major obstacle to the success of cancer treatment. An accurate
understanding and recognition of tumour heterogeneity is critical in the clinical management of cancer
patients. Here, we utilised single-cell RNA sequencing (scRNA-seq) to uncover the intra- and intertumoural heterogeneity of liver metastases from a patient with metastatic uveal melanoma. The two
metastases analysed were largely infiltrated by non-cancerous cells with significant variability in the
proportion of different cell types. Analysis of copy number variations (CNVs) showed gain of 8q and
loss of 6q in both tumours, but loss of chromosome 3 was only detected in one of the tumours. SNP
array revealed a uniparental isodisomy 3 in the tumour with two copies of chromosome 3, indicating a
re-gain of chromosome 3 during the development of the metastatic disease. In addition, both tumours
harboured subclones with additional CNVs. Pathway enrichment analysis of differentially expressed
genes revealed that cancer cells in the metastasis with isodisomy 3 showed up-regulation in epithelialmesenchymal transition and myogenesis related genes. In contrast, upregulation in interferon signalling
was observed in the metastasis with monosomy 3 and increased T-cell infiltrate. This study highlights
the complexity and heterogeneity of different metastases within an individual case of uveal melanoma.
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INTRODUCTION
Uveal melanoma (UM) is the second most common subtype of melanoma. Although the primary UM
can be controlled by either surgery or radiation brachytherapy, distant metastases eventually develop
in up to 50% of UM patients (Krantz et al. 2017). The liver is the initial metastatic site in the
overwhelming majority of cases (95%) (Willson et al. 2001). There is no consensus on the treatment to
metastatic UM, and the median overall survival is about 1 year (Khoja et al. 2019; Rantala et al. 2019).
Recent results suggest that treatment with tebentafusp or combination immunotherapy using nivolumab
and ipilimumab provide some clinical benefit (Middleton et al. 2020; Pelster et al. 2021). However, more
effective treatments for metastatic UM are still urgently needed. Once metastatic disease develops, 80%
and 92% of the patients die within 1 and 2 years, respectively (Diener-West et al. 2005; Jovanovic et
al. 2013). The molecular subtypes of UM have been defined based on their gene expression profile
(GEP), chromosome copy number variations (CNVs) and key driving mutations (Onken et al. 2004;
Royer-Bertrand et al. 2016; Robertson et al. 2017; Jager et al. 2018; Beasley et al. 2020). Two
prognostically favourable subtypes, which have either a low (Group A) or an intermediate (Group B)
metastatic risk, are associated with disomy 3 and Class 1 GEP, possess mutations in EIF1AX (Group
A) or SF3B1 (Group B), and harbour two (Group A) or more (Group B) copies of chromosome 8q. In
contrast, two prognostically unfavourable subtypes, which are associated with a high metastatic risk,
show monosomy 3 and Class 2 GEP, inactivation of BAP1 and an extra copy of chromosome 8q (Group
C) or multiple copies of chromosome 8q (Group D). Group D is also associated with significant
inflammation and immune infiltrate.
It has been well recognised that tumour heterogeneity poses a significant challenge in the management
of cancer patients (Bedard et al. 2013). The heterogeneity of liver metastases in UM is underinvestigated due to both rarity of the disease and the fact that surgical removal is not a standard practice
for UM patients with liver metastasis. Nonetheless, Krishna and colleagues demonstrated the
intersegmental heterogeneity of the immune signatures in UM metastases using bulk analysis (Krishna
et al. 2020). In the past decade, single-cell RNA sequencing (scRNA-seq) has been developed as a
powerful tool to identify and study tumour heterogeneity (Kolodziejczyk et al. 2015). Here, we
characterise the genomic profile of two concurrent liver metastases from a patient with UM using
scRNA-seq and copy number alteration analysis. We further compare the molecular results to the
clinical characteristics, to exemplify the heterogeneity of metastatic UM tumours.

RESULTS
Clinical presentation
A 69-year-old male was diagnosed with choroidal UM in his left eye in 2014 (labelled as week 0) and
was enrolled in our study prior to Iodine125 plaque insertion (Figure 1A). The patient was followed up
clinically with direct eye examination for local surveillance and six-monthly positron emission
tomography (PET) scans to monitor for metastatic disease. An isolated liver lesion (56 mm) in segment
III was identified on imaging during his follow-up. The patient underwent a partial liver resection of this
lesion at week 165. Histopathology confirmed metastatic uveal melanoma. Postoperatively, he had no
other identified metastases and re-commenced active surveillance. At week 202, he underwent
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enucleation of the left eye due to local recurrence. At week 246, an intensely FDG-avid liver lesion was
identified in the left lateral liver segment by PET (Figure 1B). At week 253, the patient underwent a
second operation, during which several variably pigmented abnormal nodules were identified
macroscopically, ranging from less than 1 to 17 mm in maximum diameter. Two separate metastatic
lesions were resected, providing the specimens described here. After surgery, a restaging PET scan at
week 255 indicated further liver metastases in segment VIII and segment VI/VII, which were not
previously evident. The patient was commenced on combination immunotherapy with ipilimumab and
nivolumab at week 256, but only completed two doses due to the development of grade III immunerelated hepatitis. Liver toxicity improved but did not completely dissipate with high dose steroids,
therefore, mycophenolate was added. A restaging scan at week 266 showed marked hepatomegaly
and upper abdominal disease in addition to two new bone metastases. At week 267, therapy continued
with single-agent nivolumab only for three more cycles and the patient died soon after from advanced
metastatic UM.

Histopathological characteristics
The enucleated left eye at week 202 contained a large choroidal melanoma (14 × 6 mm), predominantly
composed of epithelioid cells according to Callender classification. The tumour was partly necrotic with
evidence of radiation-induced tumour reduction/necrosis affecting approximately 40% of the total
tumour volume. There was also evidence of trans-scleral invasion (to conjunctival stroma). The optic
nerve margin was uninvolved.
Representative samples for the two metastatic nodules resected from the left lateral liver segment at
week 253 were harvested for molecular studies and labelled as WL02 and WL03. Histopathological
examination revealed that the tumour cells in WL02 were composed of a combination of spindle and
epithelioid cells, while the tumour cells in WL03 had a purely epithelioid appearance (Figure 1C). Both
WL02 and WL03 consisted of tumour cells showing enlarged pleomorphic round to oval nuclei, often
prominent nucleoli and moderately abundant eosinophilic cytoplasm with varying melanin pigmentation.
A variable number of admixed lymphocytes, macrophages and stromal cells (including hepatic stellate
cells) were present in the milieu surrounding these nodules, with the WL02 sample showing widespread
areas with an oedematous stroma containing a high proportion of stromal cells and macrophages while
WL03 contained areas rich in lymphocytes, particularly at the interface between the tumour and native
liver tissue.

Genomic analysis
A tissue sample of the primary tumour was analysed at the time of radiation plaque insertion by multiplex
ligation-dependent probe amplification (MLPA) (Supplementary Figure 1A). The tumour was suggested
to be of high metastatic risk based on the cytogenetic findings including loss of chromosome 1p, loss
of chromosome 3 and gain of chromosome 8q.
WL02 and WL03 metastatic nodules were analysed using droplet-based scRNA-seq. After quality
control, a total of 1,225 and 5,116 high-quality single cells were recovered from WL02 and WL03,
respectively. Based on the expression of a panel of canonical marker genes, all the cells were manually
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annotated into 11 groups (Figure 2A). Both tumours were heavily infiltrated by non-neoplastic cells
(76.73% vs 82.86%) including hepatic stellate cells (HSCs) and immune cells, with tumour cells
constituting 17-23% of the cells sequenced (Figure 2B). The two tumours differed in the proportion of
non-tumour cell types in their microenvironment, with WL03 presenting a large T-cell infiltrate (54%).
WL02 was enriched in HSCs (36%) and endothelial cells (7%) compared to WL03, which only had a
low percentage of both cell types (1.9% of each). Both tumours contained a similar number of
macrophages (9.71% vs 9.77%). Tumour cells in WL02 were more proliferative as evidenced by high
proportion of cells in S and G2M phases, while WL03 manifested quiescent characteristic with a high
proportion of tumour cells in G1 phase (Figure 2C).
Comparison of tumour cells in WL02 and WL03 by gene set enrichment analysis (GSEA) indicated that
genes involved in epithelial-mesenchymal transition (EMT), myogenesis, coagulation and hypoxia were
significantly enriched in WL02 (Figure 2D). Conversely, genes involved in immune-related pathways
such as interferon gamma and alpha response were significantly enriched in WL03, which was
consistent with the high abundance of T cell infiltrate observed in this tumour (Figure 1C and 2B).
We examined CNVs in the tumour cells from these two metastases using inferCNV (Figure 3A).
Hierarchical clustering indicated gain of 8q and loss of 6q in both tumours consistent with the primary
tumour genotype, but loss of chromosome 3 was only apparent in WL03. The main CNV profile
identified by inferCNV, including gain of 8q and loss of 6q in both tumours, and loss of chromosome 3
in WL03, was confirmed by low pass whole genome sequencing (LP-WGS) (Figure 3B) and by array
comparative genomic hybridisation (aCGH) (Supplementary Figure 1B). Targeted sequencing revealed
in BAP1 E182V mutation in both WL02 and WL03.
In addition, inferCNV revealed the development of subclones within each tumour whereas a subclone
(clone K) carrying gains of 5q,15p and 21 was found within WL02, while a subclone (clone I) carrying
gain of 2p was found within WL03 (Figure 3C). These analyses also indicated several distinct CNVs
between these two tumours, with gain of 7p, partial gain and loss of 11q uniquely observed in WL02.
Conversely, gains of 1q, 4p, 6p and 16p, and loss of 16q were found in WL03, but were not evident in
WL02.
Overall, the major discordance between the two tumours was the lack of monosomy 3 in WL02. SNP
array analysis indicated uniparental isodisomy of chromosome 3 in WL02 (Figure 3D). Isodisomy 3 in
WL02 did not reconstitute the expression of BAP1, indicated by the lack of mRNA expression
(Supplementary Figure 2A), further validated by the lack of BAP1 expression in the corresponding
formalin-fixed paraffin-embedded (FFPE) blocks (Figure 4A). However, GEP of a few genes was slightly
shifted in tumour cells from WL02 compared with WL03. These included expression of CDH1, ECM1,
EIF1B, FXR1 and HTR2B, which are associated with UM risk classification, suggesting gene expression
profile trend towards a Class 1 GEP subtype (Figure 4B).

DISCUSSION
The results of the presented study demonstrated a significant inter- and intra-tumour heterogeneity in
two spatially separated liver metastases of UM at the single-cell level. Tumour cells in WL02 showed
migratory properties with an enrichment of genes involved in EMT, myogenesis, coagulation and
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hypoxia. These cells were also found to be in an active proliferative state. Altogether this suggests a
high migratory and invasive propensity, which was further supported by the evidence of widespread
metastases detected in other liver segments, lymph node and bone in subsequent PET scans.
Our analysis shows that cells from a primary tumour with monosomy 3 could re-gain a copy of this
chromosome in the form of isodisomy 3 in all tumour cells in one of its metastatic deposits, and not the
other. The lack of BAP1 expression in the presence of 2 copies of chromosome 3 in this metastatic
deposit suggests duplication of the chromosome harbouring an inactivating mutation in BAP1 allele.
Loss of BAP1 expression is associated with a Class 2 GEP (Harbour et al. 2010; Robertson et al. 2017),
and a recent study demonstrated that the reintroduction of a wild-type BAP1 copy in vitro could shift the
GEP towards a Class 1 subtype (Karlsson et al. 2020). Conversely, it can be speculated that isodisomy
3 without a functional BAP1 in WL02 could still partially reverse the GEP to a Class 1 subtype, if there
were other factors on chromosome 3 which were involved in the regulation of the GEP. It is unclear how
chromosome 3 duplication may benefit disease progression once metastatic disease is stablished.
However, it could represent a lack of pressure to maintain a Class 2 GEP at the late stage of the disease.
Notably, isodisomy 3 as well as losses of 1p, 6q and gains of 1q, 8q have been reported to be acquired
during the metastatic stage (Rodrigues et al. 2019), suggesting that restoration of heterozygosity may
provide a selective advantage at the metastatic stage.
Loss of chromosome 9p has been observed in a quarter of UM (Harbour 2012), similarly, our analysis
showed a loss of chromosome 9 in WL02 (Figure 3B). Chromosome 9p loss has been associated with
loss of CDKDN2, resulting in a higher proliferative state of tumour cells as observed in WL02, implied
by the cell-cycle scoring analysis. Interestingly, we also found that WL02 harboured the loss of
chromosome 9, concurrently having a higher level of 8q gain, which is consistent with the proposed
evolutive pattern of metastatic UM (Shain et al. 2019).
In a recent study, Pandiani et al. used scRNA-seq to study intra-tumoural heterogeneity in primary UM
(Pandiani et al. 2021), and demonstrated the critical role of HES6 in enhancing growth and motile ability
of primary UM. Our data showed increased expression of HES6 in both liver metastases
(Supplementary Figure 2B). However, the tumour (WL02) with more proliferative and motile
characteristics had a lower HES6 expression, suggesting that this metastatic tumour might have relied
on alternative signalling to promote proliferation and migration.
A recent study in cutaneous melanoma demonstrated that CNVs can influence the local immune
composition and chromosome 7 gain was attributed to a low leukocyte infiltrate in the tumour
microenvironment (Mitra et al. 2020). In agreement with this study, WL02 harbouring a gain of 7p
showed a lower T-cell density compared to WL03. Concomitantly, WL02 had a large proportion of HSCs
infiltrate. As demonstrated in a previous study (Yu et al. 2004), HSCs can suppress T-cell infiltration,
suggesting that HSCs may have also affected the reduced T cell composition in this sample. These
observations signify a potential differential sensitivity in response to immune checkpoint inhibitors in
these two separate tumours.
The expression of immune checkpoint proteins in T cells in both tumour was consistent with the previous
studies (Supplementary Figure 2C) (Durante et al. 2020; Karlsson et al. 2020). T cells did not express
HAVCR2 (TIM-3) or PDCD1 (PD-1). The latter could explain why nivolumab, after discontinuation of
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combination immunotherapy, was ineffective in this patient. On the other hand, LAG3 was strongly
expressed in T cells in WL03, but not in T cells in WL02. This heterogeneity amongst UM metastatic
deposits may have future therapeutic implications as LAG3 blockade is pursued as promising treatment
for cancer (Atkinson et al. 2020).
In summary, this case study highlights the complexity of UM liver metastases, broadening the spectrum
of transcriptome landscape in such tumours at a single-cell level. More importantly, it emphasises the
significance of an accurate assessment of inter- and intra-tumoural heterogeneity for delivering the most
specific and personalised therapeutic intervention at the right time for patients.

METHODS
Patient and Sample Collection
Resected tumours were triaged by pathologist immediately after surgery and immersed into RPMI 1640
supplemented with 20% foetal bovine serum, 10,000 U/mL penicillin and 10,000 µg/mL streptomycin
(ThermoFisher Scientific) at 4°C to maximise the viability of cells. A fraction of each tumour was freshly
subjected to single-cell dissociation while the rest was processed as FFPE blocks for histopathology
analysis.
Preparation of Single-cell Suspension
Tumours obtained from the surgery were freshly subjected to single-cell dissociation using Human
Tumour Dissociation Kit (Miltenyi Biotec) according to the manufacturer’s instructions. Briefly, the
tumours were washed with plain RPMI (ThermoFisher Scientific) supplemented with Penicillin and
Streptomycin (ThermoFisher Scientific), and processed into pieces (1 mm3) using scalpels with the
recommended volume of enzyme mix as per instructions. The tumour pieces and enzyme mix were
then transferred into gentleMACS™ C tubes (Miltenyi Biotec), and then the tubes were loaded onto the
gentleMACS™ Octo Dissociator with Heaters (Miltenyi Biotec) with the program according to the
manufacturer’s instructions. After incubation, digested tissues were filtered through Falcon® 70-μm
strainers (Corning) and washed. Cell suspension was further filtered through 40-μm strainers to remove
cell clumps. The viability was assessed by ReadyProbe® Cell Viability Imaging Kit (ThermoFisher
Scientific) to ensure the viability was greater than 90%.
Single-Cell RNA Sequencing and Analysis
Single-cell RNA sequencing was performed using Chromium Single Cell 3’ Reagent Kits v3 (10x
Genomics) according to the manufacturer’s protocol. WL02 was aimed with a targeted capture of 2,000
cells due to the limited tissue obtained from the surgery, while WL03 with a targeted capture of 9,000
cells. Gel Beads-in-emulsion was generated using Chromium Single Cell B Chip Kit. Libraries were
sequenced using the Illumina NovaSeq 6000 and S2 flow cells (100 cycle kit) with a read one length of
28 cycles and a read two length of 94 cycles.
Raw data was processed as described previously (Denisenko et al. 2020). Briefly, BCL files were
demultiplexed and converted into FASTQ using bcl2fastq utility of Illumina BaseSpace Sequence Hub.
FASTQ files were processed using Cell Ranger 3.0.2 with refdata-cellranger-GRCh38-3.0.0 reference.
Raw gene-barcode matrices from Cell Ranger output were used for downstream processing. Cells were
distinguished from background noise using EmptyDrops (Lun et al. 2019). Outlier cells with high ratio
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of number of detected UMI to genes (> 3 median absolute deviations from median) were removed using
Scater (McCarthy et al. 2017). The pre-processed data from these two tumours was then integrated in
R (version 3.6.2) (Team 2013) with the SCTransform workflow using Seurat toolkit (version 3.2.3)
(Stuart et al. 2019). Quality control was performed by retaining cells with nCount_RNA greater than 400,
nFeature_RNA greater than 100 but less than 8000, and mitochondrial content less than 10 percent.
CellCycleScoring() function was used to predict the phases of each cell according to Seurat tutorial. In
SCTransform() function, percent of mitochondrial content was used in “vars.to.regress” argument to
regress out variation. In FindIntegrationAnchors() function, WL02 was used as a reference dataset as
it contained less doublets. The first 30 principal components were used in RunUMAP() and
FindNeighbors() functions, while the resolution parameter was set to 2 in FindCluster() function. For
other parameters unspecified above, default values were used in the SCTransform workflow.
Clusters were visualised in a two-dimensional unified manifold approximation and projection (UMAP)
and were annotated using canonical marker genes based on literature (MacParland et al. 2018; Durante
et al. 2020; Sharma et al. 2020; Zhao et al. 2020). The marker genes were as listed below: tumour cells
(MLANA, MITF, DCT), hepatic stellate cells (ACTA2, COL1A1, COL1A2, TAGLN, COL3A1, RBP1,
SPARC), endothelial cells (PECAM1, VWF), NK cells (KLRF1), T cells (CD3D), B cells (CD19, CD79A,
MS4A1), Plasma cells (IGHG1, MZB1, SDC1, CD79A), plasmacytoid dendritic cells (LILR4, GZMB),
dendritic cells (CLEC9A, CD1C, CD1E), monocytes (S100A8, S100A9, S100A12), and macrophages
(CD163, IL10, C1QA, C1QB, C1QC).
GSEA
To obtain differentially expressed genes in tumour cells between WL02 and WL03, FindMarkers()
function from Seurat package (version 3.2.3) was used (Stuart et al. 2019). GSEA software (version
4.1.0, http://www.gsea-msigdb.org/gsea/downloads.jsp) for Linux was used to calculate hallmark gene
set enrichment (h.all.v7.2.symbols.gmt) using GSEAPreanked and Log2 fold change. Hallmark
normalised enrichment score (NES) was plotted against enriched pathways using R (version 4.0.4).
CNV Analysis
InferCNV (version 1.7.1) was used to predict the copy number variations from scRNA-seq data
(InferCNV of the Trinity CTAT Project: https://github.com/broadinstitute/InferCNV). To keep high-quality
T cells as normal reference cells, only T cells that had no expression of PRAME, HTR2B, MLANA and
MITF. A value of 0.1 was used for the “cutoff” argument and default values were used in other
unspecified arguments. Intra-tumour evolutionary trees were generated using UPyhloplot2 (version 2.3;
https://github.com/harbourlab/uphyloplot2) as described (Kurtenbach et al. 2020). Phylogenetic tree
was manually annotated using the output of UPhyloplot2 and “.pred_cnv_regions.dat” file from
InferCNV in Adobe Illustrator (version 25.2.3).
Shallow LP-WGS was used to detect CNVs from WL02 and WL03. DNA was extracted from FFPE
tissue using the AllPrep DNA/RNA Mini Kit (Qiagen). 100ng of DNA was digested using the MseI
restriction enzyme (New England Biolabs) and 200 bp libraries constructed using the NEBNext Fast
DNA Library Prep Set for Ion Torrent (New England Biolabs) to manufacturers specifications. Resultant
DNA was templated and loaded into an Ion 540 chip (ThermoFisher Scientific) at 60 pM using the Ion
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Chef (Thermofisher Scientific). Libraries were sequenced on an Ion S5 (ThermoFisher Scientific) for
520 flows. Data was uploaded and analysed using Ion Reporter (version 5.14).
CGH and SNP arrays were performed in the same FFPE derived DNA samples. For CGH assay, the
test DNA and sex mismatched human reference DNA were differentially labelled with fluorophores.
Equal quantities of the 2 DNA samples were mixed and hybridised onto a SurePrint G3 Human CGH
Microarray, 8 × 60K (Agilent) and digitally scanned to capture and quantify the relative fluorescence
intensities. The ratio of the fluorescence intensities was analysed by CytoGenomics software (Agilent)
for further analysis and detection of potential CNVs. For SNP array the Infinium HD assay was
performed utilising Illumina iScan and HumanCytoSNP FFPE-12 BeadChip array according to the
manufacturer’s protocol (Illumina, USA). The BeadChips were stained, and then imaged, using a
BeadArray Reader (Illumina). Image data were analysed with GenomeStudio (Illumina).
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FIGURE LEGENDS
Figure 1. The patient’s clinical information.
(A) Treatment history of the patient. (B) An intensely FDG-avid liver lesion (white arrows) was identified
in the left lateral segment by PET in week 246. The total lesion glycolysis was equal to 84 SUV × cm 3.
(C) H&E staining of two liver metastases WL02 and WL03. Tumour cells in WL02 (left) had a spindled
to epithelioid appearance with a relatively high number of admixed stromal cells in an oedematous
stroma, while tumour cells in WL03 (right) had an epithelioid appearance and the stroma was rich in
lymphocytes at the periphery of the tumour (H&Es, original magnification both ×350).

Figure 2. Aggregate analysis of 6,341 single cells from two liver metastases.
(A) UMAP plot of 6,341 single cells, coloured by cell types that were manually assigned to cell clusters.
(B) Pie chart of each liver metastasis showing the percentages of annotated cell types. (C) Cell cycle
distribution of tumour cells. Percentage of tumour cells in different phases of the cell cycle was
estimated in WL02 (left) and WL03 (right) using CellCycleScoring function in Seurat. (D) Gene set
enrichment analysis (GSEA) pathways enriched by differentially expressed genes of tumour cells.
Differentially enriched biological pathways are displayed ordered by the normalised enrichment score
(NES).
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Figure 3. CNV analysis of two liver metastases.
(A) Hierarchical clustering from inferCNV analysis showing CNV changes by chromosomes (columns)
for individual tumour cells (rows). Blue indicates copy gains while red indicates copy losses. (B) LPWGS analysis of two liver metastases. CNVs are denoted by horizontal lines indicating total or partial
chromosomal losses (red) or gains (blue). (C) Clonality trees of each of tumour cells in the two liver
metastases. The branches are scaled according to percentage of cells in the calculated subclone
containing the indicated CNVs. (D) SNP array-based karyotyping of WL02.

Figure 4. Analysis of gene expression in two liver metastases.
(A) Immunohistochemical staining with BAP1 antibody in WL02, note the loss of nuclear staining in
tumour cells (arrow) in the presence of positive internal control (retained nuclear staining) in endothelial
and stromal cells (asterisk) (BAP-1 IHC, original magnification ×320). (B) Ridge plots of the 15-gene
panel in tumour cells between WL02 and WL03. Red arrows indicate the direction of change in a Class
2 tumour.
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